Skip to main content

Table 2 Systemic treatment of unresectable or metastatic medullary thyroid carcinoma

From: A retrospective review of the multidisciplinary management of medullary thyroid cancer: eligibility for systemic therapy

Systemic therapy for MTC n = 98

n (%)

Metastatic disease at presentation (%)

12 (12)

Developed unresectable recurrence or metastatic disease (%)

25 (26)

Received systemic therapy for unresectable or metastatic MTC (%)

7/37 (19)

Systemic therapy givena – no.

 

 Sunitinib

3

 Sorafenib

2

 Vandetanib

3

 Temsirolimus

1

 Doxorubicin

2

Death due to MTC – no. (%)

27 (28)

 Prescribed TKI

2

 Prescribed doxorubicin

2

 Discussed TKI but did not receive therapy

5

 TKI available but never discussed

1

 TKI not available

17

  1. aSome patients received 2 or more lines of systemic therapy and are still alive on treatment
Back to article page

Thyroid Research

ISSN: 1756-6614